<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37336982</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-0048</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature reviews. Neuroscience</Title><ISOAbbreviation>Nat Rev Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alternative splicing in neurodegenerative disease and the promise of RNA therapies.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>473</EndPage><MedlinePgn>457-473</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41583-023-00717-6</ELocationID><Abstract><AbstractText>Alternative splicing generates a myriad of RNA products and protein isoforms of different functions from a single gene. Dysregulated alternative splicing has emerged as a new mechanism broadly implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer disease, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson disease and repeat expansion diseases. Understanding the mechanisms and functional outcomes of abnormal splicing in neurological disorders is vital in developing effective therapies to treat mis-splicing pathology. In this Review, we discuss emerging research and evidence of the roles of alternative splicing defects in major neurodegenerative diseases and summarize the latest advances in RNA-based therapeutic strategies to target these disorders.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nikom</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2722-6002</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, Riverside, Riverside, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for RNA Biology and Medicine, University of California, Riverside, Riverside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Sika</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0573-4981</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, Riverside, Riverside, CA, USA. sikaz@ucr.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for RNA Biology and Medicine, University of California, Riverside, Riverside, CA, USA. sikaz@ucr.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Sciences, University of California, Riverside, Riverside, CA, USA. sikaz@ucr.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH116220</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS104041</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS125276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurosci</MedlineTA><NlmUniqueID>100962781</NlmUniqueID><ISSNLinking>1471-003X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37336982</ArticleId><ArticleId IdType="doi">10.1038/s41583-023-00717-6</ArticleId><ArticleId IdType="pii">10.1038/s41583-023-00717-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chow, L. T., Gelinas, R. E., Broker, T. R. &amp; Roberts, R. J. An amazing sequence arrangement at the 5&#x2032; ends of adenovirus 2 messenger RNA. Cell 12, 1&#x2013;8 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">902310</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara, S. G., Jonas, V., Rosenfeld, M. G., Ong, E. S. &amp; Evans, R. M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298, 240&#x2013;244 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6283379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470&#x2013;476 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18978772</ArticleId><ArticleId IdType="pmc">2593745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, Q., Shai, O., Lee, L. J., Frey, B. J. &amp; Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413&#x2013;1415 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18978789</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo, G., Holste, D., Kreiman, G. &amp; Burge, C. B. Variation in alternative splicing across human tissues. Genome Biol. 5, R74 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15461793</ArticleId><ArticleId IdType="pmc">545594</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa-Morais, N. L. et al. The evolutionary landscape of alternative splicing in vertebrate species. Science 338, 1587&#x2013;1593 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23258890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong, C. K., Black, D. L. &amp; Zheng, S. The neurogenetics of alternative splicing. Nat. Rev. Neurosci. 17, 265&#x2013;281 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27094079</ArticleId><ArticleId IdType="pmc">4861142</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlanis, E. &amp; Scheiffele, P. Regulation of neuronal differentiation, function, and plasticity by alternative splicing. Annu. Rev. Cell Dev. Biol. 34, 451&#x2013;469 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30028642</ArticleId><ArticleId IdType="pmc">6697533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ule, J. &amp; Blencowe, B. J. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell 76, 329&#x2013;345 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31626751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. Alternative splicing programming of axon formation. Wiley Interdiscip. Rev. RNA 11, e1585 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31922356</ArticleId><ArticleId IdType="pmc">7594648</ArticleId></ArticleIdList></Reference><Reference><Citation>Traunm&#xfc;ller, L., Gomez, A. M., Nguyen, T.-M. &amp; Scheiffele, P. Control of neuronal synapse specification by a highly dedicated alternative splicing program. Science 352, 982&#x2013;986 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27174676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauger, O. &amp; Scheiffele, P. Beyond proteome diversity: alternative splicing as a regulator of neuronal transcript dynamics. Curr. Opin. Neurobiol. 45, 162&#x2013;168 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28609697</ArticleId><ArticleId IdType="pmc">6689270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, M. et al. Axonogenesis is coordinated by neuron-specific alternative splicing programming and splicing regulator PTBP2. Neuron 101, 690&#x2013;706.e10 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30733148</ArticleId><ArticleId IdType="pmc">6474845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, L., Zhang, M., Stoilov, P., Chen, L. &amp; Zheng, S. Developmental attenuation of neuronal apoptosis by neural-specific splicing of Bak1 microexon. Neuron 107, 1180&#x2013;1196.e8 (2020). This study demonstrates that the neuronal splicing of a microexon in Bak1 reduces apoptosis competence and is necessary for supporting neuronal and animal survival, providing genetic evidence highlighting the essential role of neuronal splicing in brain development and organism survival.</Citation><ArticleIdList><ArticleId IdType="pubmed">32710818</ArticleId><ArticleId IdType="pmc">7529960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonatopoulos-Pournatzis, T. &amp; Blencowe, B. J. Microexons: at the nexus of nervous system development, behaviour and autism spectrum disorder. Curr. Opin. Genet. Dev. 65, 22&#x2013;33 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32535349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha, K. C. H., Sterne-Weiler, T., Morris, Q., Weatheritt, R. J. &amp; Blencowe, B. J. Differential contribution of transcriptomic regulatory layers in the definition of neuronal identity. Nat. Commun. 12, 335 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33436550</ArticleId><ArticleId IdType="pmc">7804943</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong, J. K., Ergin, V., Chen, L. &amp; Zheng, S. Multilayered regulations of alternative splicing, NMD, and protein stability control temporal induction and tissue-specific expression of TRIM46 during axon formation. Nat. Commun. 13, 2081 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35440129</ArticleId><ArticleId IdType="pmc">9019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. et al. PSD-95 is post-transcriptionally repressed during early neural development by PTBP1 and PTBP2. Nat. Neurosci. 15, 381&#x2013;388 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22246437</ArticleId><ArticleId IdType="pmc">3288398</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. et al. Cell type-specific alternative splicing governs cell fate in the developing cerebral cortex. Cell 166, 1147&#x2013;1162.e15 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27565344</ArticleId><ArticleId IdType="pmc">5248659</ArticleId></ArticleIdList></Reference><Reference><Citation>Havens, M. A. &amp; Hastings, M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 44, 6549&#x2013;6563 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27288447</ArticleId><ArticleId IdType="pmc">5001604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, C. F., Krainer, A. R. &amp; Cleveland, D. W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. Neurosci. 42, 385&#x2013;406 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31283897</ArticleId><ArticleId IdType="pmc">7427431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasaki, H., Arita, M., Nishizawa, T., Suwa, M. &amp; Gotoh, O. Species-specific variation of alternative splicing and transcriptional initiation in six eukaryotes. Gene 364, 53&#x2013;62 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16219431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, M. &amp; Manley, J. L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741&#x2013;754 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19773805</ArticleId><ArticleId IdType="pmc">2958924</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Blanco, M. A., Baraniak, A. P. &amp; Lasda, E. L. Alternative splicing in disease and therapy. Nat. Biotechnol. 22, 535&#x2013;546 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15122293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ule, J. et al. An RNA map predicting Nova-dependent splicing regulation. Nature 444, 580&#x2013;586 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17065982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegener, M. &amp; M&#xfc;ller-McNicoll, M. in The Biology of mRNA: Structure and Function (eds Oeffinger, M. &amp; Zenklusen, D.) 83&#x2013;112 (Springer International, 2019).</Citation></Reference><Reference><Citation>C&#xe1;ceres, J. F. &amp; Kornblihtt, A. R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18, 186&#x2013;193 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, X.-D. &amp; Ares, M. Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 15, 689&#x2013;701 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25112293</ArticleId><ArticleId IdType="pmc">4440546</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, C.-H., Dhananjaya, D. &amp; Tarn, W.-Y. Alternative splicing in neurogenesis and brain development. Front. Mol. Biosci. 5, 12 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29484299</ArticleId><ArticleId IdType="pmc">5816070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkura, N., Takahashi, M., Yaguchi, H., Nagamura, Y. &amp; Tsukada, T. Coactivator-associated arginine methyltransferase 1, CARM1, affects pre-mRNA splicing in an isoform-specific manner. J. Biol. Chem. 280, 28927&#x2013;28935 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15944154</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, D., C&#xf4;t&#xe9;, J., Shaaban, S. &amp; Bedford, M. T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 25, 71&#x2013;83 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17218272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y.-C. et al. Protein arginine methylation facilitates cotranscriptional recruitment of pre-mRNA splicing factors. Mol. Cell Biol. 30, 5245&#x2013;5256 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20823272</ArticleId><ArticleId IdType="pmc">2953043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunderson, F. Q. &amp; Johnson, T. L. Acetylation by the transcriptional coactivator Gcn5 plays a novel role in co-transcriptional spliceosome assembly. PLoS Genet. 5, e1000682 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19834536</ArticleId><ArticleId IdType="pmc">2752994</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, E. et al. Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol. Cell Biol. 21, 6782&#x2013;6795 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11564863</ArticleId><ArticleId IdType="pmc">99856</ArticleId></ArticleIdList></Reference><Reference><Citation>Naftelberg, S., Schor, I. E., Ast, G. &amp; Kornblihtt, A. R. Regulation of alternative splicing through coupling with transcription and chromatin structure. Annu. Rev. Biochem. 84, 165&#x2013;198 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26034889</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren, H., Lev-Maor, G. &amp; Ast, G. Alternative splicing and evolution: diversification, exon definition and function. Nat. Rev. Genet. 11, 345&#x2013;355 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20376054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, L.-Y., Zhu, Y.-R., Dai, D.-J., Wang, X. &amp; Jin, H.-C. Epigenetic regulation of alternative splicing. Am. J. Cancer Res. 8, 2346&#x2013;2358 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30662796</ArticleId><ArticleId IdType="pmc">6325479</ArticleId></ArticleIdList></Reference><Reference><Citation>Luco, R. F., Allo, M., Schor, I. E., Kornblihtt, A. R. &amp; Misteli, T. Epigenetics in alternative pre-mRNA splicing. Cell 144, 16&#x2013;26 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21215366</ArticleId><ArticleId IdType="pmc">3038581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahhal, R. &amp; Seto, E. Emerging roles of histone modifications and HDACs in RNA splicing. Nucleic Acids Res. 47, 4911&#x2013;4926 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31162605</ArticleId><ArticleId IdType="pmc">6547430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, J., Zhang, Y.-Z., Jiang, J. &amp; Duan, C.-G. The crosstalk between epigenetic mechanisms and alternative RNA processing regulation. Front. Genet. 11, 998 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32973889</ArticleId><ArticleId IdType="pmc">7472560</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews, K. A. et al. Racial and ethnic estimates of Alzheimer&#x2019;s disease and related dementias in the United States (2015&#x2013;2060) in adults aged &#x2265;65 years. Alzheimers Dement. 15, 17&#x2013;24 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30243772</ArticleId></ArticleIdList></Reference><Reference><Citation>Killin, L. O. J., Starr, J. M., Shiue, I. J. &amp; Russ, T. C. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 16, 175 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27729011</ArticleId><ArticleId IdType="pmc">5059894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner, L. M. &amp; G&#xf6;tz, J. Amyloid-&#x3b2; and tau-a toxic pas de deux in Alzheimer&#x2019;s disease. Nat. Rev. Neurosci. 12, 65&#x2013;72 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, J. E., Hayden, E. J. &amp; Rohn, T. T. Alternative splicing in Alzheimer&#x2019;s disease. J. Parkinsons Dis. Alzheimers Dis. 2, 6 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26942228</ArticleId><ArticleId IdType="pmc">4772657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton, M. et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705 (1998). Together with Spillantini et al. (1998), this study reveals mutations in the splice sites of the MAPT gene causative for FTDP-17, which uncovered the key role of 3R-tau:4R-tau isoform balance in neurodegenerative pathology.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737&#x2013;7741 (1998). Together with Hutton et al. (1998), this study reveals mutations in the splice sites of the MAPT gene causative for FTDP-17, which uncovered the key role of 3R-tau:4R-tau isoform balance in neurodegenerative pathology.</Citation><ArticleIdList><ArticleId IdType="pubmed">9636220</ArticleId><ArticleId IdType="pmc">22742</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815&#x2013;825 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Wu, K.-M., Yang, L., Dong, Q. &amp; Yu, J.-T. Tauopathies: new perspectives and challenges. Mol. Neurodegener. 17, 28 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35392986</ArticleId><ArticleId IdType="pmc">8991707</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang, K. H., Golde, T. E. &amp; Giasson, B. I. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab. Invest. 99, 912&#x2013;928 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30742061</ArticleId><ArticleId IdType="pmc">7289372</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F. &amp; Gong, C.-X. Tau exon 10 alternative splicing and tauopathies. Mol. Neurodegener. 3, 8 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18616804</ArticleId><ArticleId IdType="pmc">2483273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutreja, Y., Combs, B. &amp; Gamblin, T. C. FTDP-17 mutations alter the aggregation and microtubule stabilization propensity of tau in an isoform-specific fashion. Biochemistry 58, 742&#x2013;754 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30562452</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock, M. &amp; Gallo, J.-M. Tau alternative splicing in familial and sporadic tauopathies. Biochem. Soc. Trans. 40, 677&#x2013;680 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22817715</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. &amp; Crowther, R. A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M. &amp; Mandelkow, E. Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511&#x2013;9522 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode, B. L., Chau, M., Denis, P. E. &amp; Feinstein, S. C. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenerative disease. J. Biol. Chem. 275, 38182&#x2013;38189 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10984497</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J. &amp; Crowther, R. A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393&#x2013;399 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2498079</ArticleId><ArticleId IdType="pmc">400819</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini, M. G. &amp; Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, J. et al. Rbfox3/NeuN regulates alternative splicing of tau exon 10. J. Alzheimer&#x2019;s Dis. 66, 1695&#x2013;1704 (2018).</Citation></Reference><Reference><Citation>Qian, W. &amp; Liu, F. Regulation of alternative splicing of tau exon 10. Neurosci. Bull. 30, 367&#x2013;377 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24627328</ArticleId><ArticleId IdType="pmc">5562657</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M. &amp; Jakes, R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9, 4225&#x2013;4230 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2124967</ArticleId><ArticleId IdType="pmc">552204</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;sler, T. W. et al. Four-repeat tauopathies. Prog. Neurobiol. 180, 101644 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31238088</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford, P. M. et al. Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain 126, 814&#x2013;826 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12615641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacovich, V. et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J. Neurosci. 37, 58&#x2013;69 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28053030</ArticleId><ArticleId IdType="pmc">6705673</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian, W. et al. Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res. 39, 6161&#x2013;6171 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21470964</ArticleId><ArticleId IdType="pmc">3152345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, J. et al. Cyclic AMP-dependent protein kinase regulates 9G8-mediated alternative splicing of tau exon 10. FEBS Lett. 586, 2239&#x2013;2244 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22677170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez, F. et al. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35: implications for Alzheimer&#x2019;s disease. J. Biol. Chem. 279, 3801&#x2013;3806 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14602710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, Q., Guo, J. &amp; Zhou, J. A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. J. Neurochem. 90, 164&#x2013;172 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15198676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo, S. et al. Tra2&#x3b2;, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. Genes Cell 9, 121&#x2013;130 (2004).</Citation></Reference><Reference><Citation>Wang, J. et al. Tau exon 10, whose missplicing causes frontotemporal dementia, is regulated by an intricate interplay of cis elements and trans factors. J. Neurochem. 88, 1078&#x2013;1090 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15009664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, J. Y., Kar, A., Kuo, D., Yu, B. &amp; Havlioglu, N. SRp54 (SFRS11), a regulator for tau exon 10 alternative splicing identified by an expression cloning strategy. Mol. Cell Biol. 26, 6739&#x2013;6747 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16943417</ArticleId><ArticleId IdType="pmc">1592875</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, Z. et al. Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2&#x3b2;. J. Biol. Chem. 278, 18997&#x2013;19007 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12649279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, L., Wang, J., Wang, Y. &amp; Andreadis, A. SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations. Mol. Cell Neurosci. 34, 48&#x2013;58 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17137791</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza, I. &amp; Schellenberg, G. D. Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations &#x394;280K AND N279K. J. Biol. Chem. 281, 2460&#x2013;2469 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16308321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke, Y. et al. Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer&#x2019;s and Pick&#x2019;s disease. PLoS ONE 7, e35678 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22558197</ArticleId><ArticleId IdType="pmc">3338448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, J., Shu, R. &amp; Zhu, Y. Dysregulation and dislocation of SFPQ disturbed DNA organization in Alzheimer&#x2019;s disease and frontotemporal dementia. J. Alzheimers Dis. 61, 1311&#x2013;1321 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29376859</ArticleId></ArticleIdList></Reference><Reference><Citation>Younas, N. et al. SFPQ and tau: critical factors contributing to rapid progression of Alzheimer&#x2019;s disease. Acta Neuropathol. 140, 317&#x2013;339 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32577828</ArticleId><ArticleId IdType="pmc">7423812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray, P. et al. PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10. J. Mol. Neurosci. 45, 453&#x2013;466 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21881826</ArticleId><ArticleId IdType="pmc">3893066</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing, S. et al. Identification of HnRNPC as a novel tau exon 10 splicing factor using RNA antisense purification mass spectrometry. RNA Biol. 19, 104&#x2013;116 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34965173</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova, I., Karran, E. &amp; De Strooper, B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349&#x2013;357 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu, T., Liu, Q., Chen, Y.-X., Zhao, Y.-F. &amp; Li, Y.-M. A&#x3b2;42 and A&#x3b2;40: similarities and differences. J. Pept. Sci. 21, 522&#x2013;529 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26018760</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C.-C. et al. Synergistic interactions between Alzheimer&#x2019;s A&#x3b2;40 and A&#x3b2;42 on the surface of primary neurons revealed by single molecule microscopy. PLoS ONE 8, e82139 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24312636</ArticleId><ArticleId IdType="pmc">3847093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan, M. et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of &#x3b2;-amyloid. Nat. Genet. 1, 345&#x2013;347 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Finckh, U. et al. Novel mutations and repeated findings of mutations in familial Alzheimer disease. Neurogenetics 6, 85&#x2013;89 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15776278</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan, C.-L., Zhang, T. &amp; Lee, T. H. The genetics of Alzheimer&#x2019;s disease in the Chinese population. Int. J. Mol. Sci. 21, 2381 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32235595</ArticleId><ArticleId IdType="pmc">7178026</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch, C. M. &amp; Goate, A. M. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Neve, R. L., Finch, E. A. &amp; Dawes, L. R. Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron 1, 669&#x2013;677 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2908447</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi, R. E. et al. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer&#x2019;s disease. Nature 331, 528&#x2013;530 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2893290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Modifications and trafficking of APP in the pathogenesis of Alzheimer&#x2019;s disease. Front. Mol. Neurosci. 10, 294 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28966576</ArticleId><ArticleId IdType="pmc">5605621</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde, T. E., Estus, S., Usiak, M., Younkin, L. H. &amp; Younkin, S. G. Expression of &#x3b2; amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer&#x2019;s disease using PCR. Neuron 4, 253&#x2013;267 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2106330</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui, T. et al. Expression of APP pathway mRNAs and proteins in Alzheimer&#x2019;s disease. Brain Res. 1161, 116&#x2013;123 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17586478</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrachina, M. et al. Amyloid-&#x3b2; deposition in the cerebral cortex in dementia with Lewy bodies is accompanied by a relative increase in A&#x3b2;PP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem. Int. 46, 253&#x2013;260 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15670642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan, S. S., Sandbrink, R., Beyreuther, K. &amp; Schmitt, H. P. APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer&#x2019;s disease and non-demented aged subjects: a multifactorial analysis. Clin. Neuropathol. 14, 142&#x2013;149 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7671455</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, S. A., McNeill, T., Cordell, B. &amp; Finch, C. E. Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer&#x2019;s disease. Science 248, 854&#x2013;857 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir, R. D. et al. Relative increase in Alzheimer&#x2019;s disease of soluble forms of cerebral A&#x3b2; amyloid protein precursor containing the Kunitz protease inhibitory domain. J. Biol. Chem. 273, 5013&#x2013;5019 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, S. et al. Identification of exon skipping events associated with Alzheimer&#x2019;s disease in the human hippocampus. BMC Med. Genomics 12, 13 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30704480</ArticleId><ArticleId IdType="pmc">6357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, S., Nakamura, S. &amp; Ueda, K. [Expression of amyloid beta-protein gene in Alzheimer&#x2019;s disease]. Rinsho Byori 38, 489&#x2013;493 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2116540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, L., Fukuchi, K. &amp; Younkin, S. G. The alternatively spliced Kunitz protease inhibitor domain alters amyloid &#x3b2; protein precursor processing and amyloid &#x3b2; protein production in cultured cells. J. Biol. Chem. 271, 30929&#x2013;30934 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8940079</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyaev, N. D. et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a &#x3b2;-secretase-dependent pathway. J. Biol. Chem. 285, 41443&#x2013;41454 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20961856</ArticleId><ArticleId IdType="pmc">3009870</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalifa, N. B. et al. Contribution of Kunitz protease inhibitor and transmembrane domains to amyloid precursor protein homodimerization. Neurodegener. Dis. 10, 92&#x2013;95 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22343802</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert, S. et al. Dimerization leads to changes in APP (amyloid precursor protein) trafficking mediated by LRP1 and SorLA. Cell. Mol. Life Sci. 75, 301&#x2013;322 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28799085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua, L.-M., Lim, M.-L. &amp; Wong, B.-S. The Kunitz-protease inhibitor domain in amyloid precursor protein reduces cellular mitochondrial enzymes expression and function. Biochem. Biophys. Res. Commun. 437, 642&#x2013;647 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23872114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wamsley, B. et al. Rbfox1 mediates cell-type-specific splicing in cortical interneurons. Neuron 100, 846&#x2013;859.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30318414</ArticleId><ArticleId IdType="pmc">6541232</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam, S., Suzuki, H. &amp; Tsukahara, T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochem. Int. 78, 7&#x2013;17 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkallas, R., Fish, L., Goodarzi, H. &amp; Najafabadi, H. S. Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer&#x2019;s disease. Nat. Commun. 8, 909 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29030541</ArticleId><ArticleId IdType="pmc">5714957</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong, J. K. et al. PTBP1 and PTBP2 serve both specific and redundant functions in neuronal pre-mRNA splicing. Cell Rep. 17, 2766&#x2013;2775 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27926877</ArticleId><ArticleId IdType="pmc">5179036</ArticleId></ArticleIdList></Reference><Reference><Citation>Makeyev, E. V., Zhang, J., Carrasco, M. A. &amp; Maniatis, T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 27, 435&#x2013;448 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17679093</ArticleId><ArticleId IdType="pmc">3139456</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, P., Al Hashimi, A., Girard, J., Delay, C. &amp; H&#xe9;bert, S. S. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J. Neurochem. 116, 240&#x2013;247 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21062284</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, D., Dong, X., Zheng, D. &amp; Nao, J. MiR-124 and the underlying therapeutic promise of neurodegenerative disorders. Front. Pharmacol. 10, 01555 (2020).</Citation></Reference><Reference><Citation>Ehehalt, R. et al. Splice variants of the b-site APP-cleaving enzyme BACE1 in human brain and pancreas. Biochem. Biophys. Res. Commun. 293, 240&#x2013;247 (2002).</Citation></Reference><Reference><Citation>Holsinger, R. M. D., Goense, N., Bohorquez, J. &amp; Strappe, P. Splice variants of the Alzheimer&#x2019;s disease beta-secretase, BACE1. Neurogenetics 14, 1&#x2013;9 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23142975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mowrer, K. R. &amp; Wolfe, M. S. Promotion of BACE1 mRNA alternative splicing reduces amyloid &#x3b2;-peptide production. J. Biol. Chem. 283, 18694&#x2013;18701 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18468996</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanahashi, H. &amp; Tabira, T. Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production. Neurosci. Lett. 307, 9&#x2013;12 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11516562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolisnyk, B. et al. Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer&#x2019;s-like pathology. Cereb. Cortex 27, 3553&#x2013;3567 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27312991</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson, A. et al. Cholinergic-associated loss of hnRNP-A/B in Alzheimer&#x2019;s disease impairs cortical splicing and cognitive function in mice. EMBO Mol. Med. 4, 730&#x2013;742 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22628224</ArticleId><ArticleId IdType="pmc">3494073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolisnyk, B. et al. Cholinergic regulation of hnRNPA2/B1 translation by M1 muscarinic receptors. J. Neurosci. 36, 6287&#x2013;6296 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27277805</ArticleId><ArticleId IdType="pmc">6604881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel, H. et al. The &#x3b2;-secretase BACE1 in Alzheimer&#x2019;s disease. Biol. Psychiatry 89, 745&#x2013;756 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32223911</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. J. &amp; Hardy, J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId><ArticleId IdType="pmc">4888851</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber, C. et al. Familial Alzheimer&#x2019;s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol. Psychiatry 25, 2919&#x2013;2931 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">30980041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, L., Zhou, R., Yang, G. &amp; Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc. Natl Acad. Sci. USA 114, E476&#x2013;E485 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberg, G. D. et al. Genetic linkage evidence for a familial Alzheimer&#x2019;s disease locus on chromosome 14. Science 258, 668&#x2013;671 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1411576</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe, C. et al. Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer&#x2019;s disease by increased A&#x3b2;42 secretion. Hum. Mol. Genet. 8, 1529&#x2013;1540 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10401002</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar, L. R. et al. Genetic origin of a large family with a novel PSEN1 mutation (ILE416THR). Alzheimers Dement. 15, 709&#x2013;719 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">6511480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok, J. B. J. et al. Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer&#x2019;s disease with non-cored plaques and no neuritic dystrophy. J. Biol. Chem. 278, 6748&#x2013;6754 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12493737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev, E. I. et al. Analysis of the 5&#x2032; sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics 40, 415&#x2013;424 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9073509</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheper, W., Zwart, R. &amp; Baas, F. Alternative splicing in the N-terminus of Alzheimer&#x2019;s presenilin 1. Neurogenetics 5, 223&#x2013;227 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15480879</ArticleId></ArticleIdList></Reference><Reference><Citation>Braggin, J. E. et al. Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. Ann. Clin. Transl. Neurol. 6, 762&#x2013;777 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31020001</ArticleId><ArticleId IdType="pmc">6469258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu, G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333&#x2013;344 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19339974</ArticleId><ArticleId IdType="pmc">2908393</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, C.-C., Kanekiyo, T., Xu, H. &amp; Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23296339</ArticleId><ArticleId IdType="pmc">3726719</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, M.-X. et al. The APOE-&#x220a;4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics. J. Am. Med. Assoc. 279, 751&#x2013;755 (1998).</Citation></Reference><Reference><Citation>Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J. Am. Med. Assoc. 278, 1349&#x2013;1356 (1997).</Citation></Reference><Reference><Citation>Qian, J. et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 14, e1002254 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28323826</ArticleId><ArticleId IdType="pmc">5360223</ArticleId></ArticleIdList></Reference><Reference><Citation>Twine, N. A., Janitz, K., Wilkins, M. R. &amp; Janitz, M. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer&#x2019;s disease. PLoS ONE 6, e16266 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21283692</ArticleId><ArticleId IdType="pmc">3025006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills, J. D. et al. The alternative splicing of the apolipoprotein E gene is unperturbed in the brains of Alzheimer&#x2019;s disease patients. Mol. Biol. Rep. 41, 6365&#x2013;6376 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24996286</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Q. et al. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J. Neurosci. 28, 1452&#x2013;1459 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18256266</ArticleId><ArticleId IdType="pmc">6671590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo, C. M., Ho, A. &amp; Beffert, U. ApoER2: functional tuning through splicing. Front. Mol. Neurosci. 13, 144 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32848602</ArticleId><ArticleId IdType="pmc">7410921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25186741</ArticleId><ArticleId IdType="pmc">4152602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo, C. M., Labadorf, A. T., Ho, A. &amp; Beffert, U. Single molecule, long-read Apoer2 sequencing identifies conserved and species-specific splicing patterns. Genomics 114, 110318 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35192893</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert, U. et al. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron 47, 567&#x2013;579 (2005). This study shows that the ApoER2 alternative exon is necessary for Reelin-induced tyrosine phosphorylation of NMDA receptor subunits and hence has an important role in modulating synaptic transmission and memory processes.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrich, A. J. et al. Therapeutic correction of ApoER2 splicing in Alzheimer&#x2019;s disease mice using antisense oligonucleotides. EMBO Mol. Med. 8, 328&#x2013;345 (2016). This study targets the dysregulated splice isoforms of the Apoe receptor ApoER2 by using an ASO to promote an alternative splicing event that rescued synaptic function and alleviate cognitive defects in mice without altering total beta-amyloid levels.</Citation><ArticleIdList><ArticleId IdType="pubmed">26902204</ArticleId><ArticleId IdType="pmc">4818756</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert, U. et al. ApoE receptor 2 controls neuronal survival in the adult brain. Curr. Biol. 16, 2446&#x2013;2452 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17174920</ArticleId></ArticleIdList></Reference><Reference><Citation>Samii, A., Nutt, J. G. &amp; Ransom, B. R. Parkinson&#x2019;s disease. Lancet 363, 1783&#x2013;1793 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15172778</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini, M. G. et al. &#x3b1;-Synuclein in Lewy bodies. Nature 388, 839&#x2013;840 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9;, J. The synaptic function of &#x3b1;-synuclein. J. Parkinsons Dis. 5, 699&#x2013;713 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26407041</ArticleId><ArticleId IdType="pmc">4927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunati, A., Lesage, S. &amp; Brice, A. The genetic landscape of Parkinson&#x2019;s disease. Rev. Neurol. 174, 628&#x2013;643 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30245141</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos, M. H. et al. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson&#x2019;s disease. Science 276, 2045&#x2013;2047 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton, A. B. et al. &#x3b1;-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science 302, 841 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Benito, M. et al. Modeling Parkinson&#x2019;s disease with the &#x3b1;-synuclein protein. Front. Pharmacol. 11, 356 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32390826</ArticleId><ArticleId IdType="pmc">7191035</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, K. &amp; Ariza, A. &#x3b1;-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 47, 509&#x2013;524 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22923347</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng, E. et al. The landscape of SNCA transcripts across synucleinopathies: new insights from long reads sequencing analysis. Front. Genet. 10, 584 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31338105</ArticleId><ArticleId IdType="pmc">6629766</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion, D. et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26, 254&#x2013;257 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7601450</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, K. et al. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9, 15&#x2013;23 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17955272</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, K. et al. Differential expression of &#x3b1;-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9, 163&#x2013;172 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18335262</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, K. et al. Differential expression of &#x3b1;-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 30, 601&#x2013;607 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15541000</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean, J. R., Hallett, P. J., Cooper, O., Stanley, M. &amp; Isacson, O. Transcript expression levels of full-length &#x3b1;-synuclein and its three alternatively spliced variants in Parkinson&#x2019;s disease brain regions and in a transgenic mouse model of &#x3b1;-synuclein overexpression. Mol. Cell Neurosci. 49, 230&#x2013;239 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22155155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardo, L. F. et al. &#x3b1;-Synuclein transcript isoforms in three different brain regions from Parkinson&#x2019;s disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci. Lett. 562, 45&#x2013;49 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, K. et al. Low &#x3b1;-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. NeuroReport 17, 1327&#x2013;1330 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16951579</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudek, T. et al. Altered &#x3b1;-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains. J. Neurochem. 136, 172&#x2013;185 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26465922</ArticleId></ArticleIdList></Reference><Reference><Citation>Soll, L. G. et al. &#x3b1;-Synuclein-112 impairs synaptic vesicle recycling consistent with its enhanced membrane binding properties. Front. Cell Dev. Biol. 8, 405 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32548120</ArticleId><ArticleId IdType="pmc">7272675</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, J. J. et al. The effect of SNCA 3&#x2032; region on the levels of SNCA-112 splicing variant. Neurogenetics 12, 59&#x2013;64 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21046180</ArticleId></ArticleIdList></Reference><Reference><Citation>Manda, K. M., Yedlapudi, D., Korukonda, S., Bojja, S. &amp; Kalivendi, S. V. The chaperone-like activity of &#x3b1;-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation. PLoS ONE 9, e98657 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24892822</ArticleId><ArticleId IdType="pmc">4043908</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati, A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J. Parkinsons Dis. 6, 39&#x2013;51 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27003784</ArticleId><ArticleId IdType="pmc">4927808</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe1;mez-Valero, A. &amp; Beyer, K. Alternative splicing of &#x3b1;- and &#x3b2;-synuclein genes plays differential roles in synucleinopathies. Genes 9, 63 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29370097</ArticleId><ArticleId IdType="pmc">5852559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bungeroth, M. et al. Differential aggregation properties of &#x3b1;-synuclein isoforms. Neurobiol. Aging 35, 1913&#x2013;1919 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24629672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, S. H. et al. Emerging pathways to neurodegeneration: dissecting the critical molecular mechanisms in Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease. Biomed. Pharmacother. 111, 765&#x2013;777 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30612001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalivendi, S. V., Yedlapudi, D., Hillard, C. J. &amp; Kalyanaraman, B. Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson&#x2019;s disease. Free Radic. Biol. Med. 48, 377&#x2013;383 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19857570</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrie, E. S. et al. Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3&#x2032; UTR. Mol. Genet. Genom. Med. 6, 565&#x2013;574 (2018).</Citation></Reference><Reference><Citation>Shehadeh, L. A. et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson&#x2019;s disease. PLoS ONE 5, e9104 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20161708</ArticleId><ArticleId IdType="pmc">2817002</ArticleId></ArticleIdList></Reference><Reference><Citation>Molochnikov, L. et al. A molecular signature in blood identifies early Parkinson&#x2019;s disease. Mol. Neurodegener. 7, 26 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22651796</ArticleId><ArticleId IdType="pmc">3424147</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock, J. et al. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8, 518&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22890216</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman, D. S. &amp; Roberts, R. O. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J. Mol. Neurosci. 45, 330&#x2013;335 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21584654</ArticleId><ArticleId IdType="pmc">3208074</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger, E. C. Frontotemporal dementias. Continuum 22, 464&#x2013;489 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27042904</ArticleId><ArticleId IdType="pmc">5390934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9;, D. E. et al. Story of the ALS&#x2013;FTD continuum retold: rather two distinct entities. J. Neurol. Neurosurg. Psychiatry 90, 586&#x2013;589 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30257969</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon, Y. A., Fratta, P., Traynor, B. J. &amp; Chia, R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci. 14, 42 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32116499</ArticleId><ArticleId IdType="pmc">7012787</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti, Z. &amp; Patten, S. A. RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 9, 712 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30723494</ArticleId><ArticleId IdType="pmc">6349704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch, T. et al. Clinical characteristics of a family with chromosome 17&#x2010;linked disinhibition&#x2013;dementia&#x2013;Parkinsonism&#x2013;amyotrophy complex. Neurology 44, 1878&#x2013;1878 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7936241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmsen, K. C., Lynch, T., Pavlou, E., Higgins, M. &amp; Nygaard, T. G. Localization of disinhibition&#x2013;dementia&#x2013;parkinsonism&#x2013;amyotrophy complex to 17q21-22. Am. J. Hum. Genet. 55, 1159&#x2013;1165 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7977375</ArticleId><ArticleId IdType="pmc">1918447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sima, Aa. F. et al. The neuropathology of chromosome 17-linked dementia. Ann. Neurol. 39, 734&#x2013;743 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8651645</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId><ArticleId IdType="pmc">3202986</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId><ArticleId IdType="pmc">3200438</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323&#x2013;330 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22406228</ArticleId><ArticleId IdType="pmc">3322422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron, T. F. &amp; Petrucelli, L. Disease mechanisms of C9ORF72 repeat expansions. Cold Spring Harb. Perspect. Med. 8, a024224 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28130314</ArticleId><ArticleId IdType="pmc">5880161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y.-B. et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178&#x2013;1186 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24290757</ArticleId><ArticleId IdType="pmc">3898469</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon, E. G. et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife 5, e17820 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27623008</ArticleId><ArticleId IdType="pmc">5050020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon, I. et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25081482</ArticleId><ArticleId IdType="pmc">4459787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, S. et al. Evidence that C9ORF72 dipeptide repeat proteins associate with U2 snRNP to cause mis-splicing in ALS/FTD patients. Cell Rep. 19, 2244&#x2013;2256 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28614712</ArticleId><ArticleId IdType="pmc">5653973</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns, N. J. et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 171, 227&#x2013;240 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17591968</ArticleId><ArticleId IdType="pmc">1941578</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone, B. et al. Alternative splicing of ALS genes: misregulation and potential therapies. Cell Mol. Neurobiol. 40, 1&#x2013;14 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31385134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, J. P., Pletnikova, O., Troncoso, J. C. &amp; Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015). This study demonstrates that the loss of TDP-43 induces cryptic exon splicing in ALS&#x2013;FTD patient tissue with TDP-43 pathology.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250685</ArticleId><ArticleId IdType="pmc">4825810</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies, J.-E. et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain 141, 1320&#x2013;1333 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562314</ArticleId><ArticleId IdType="pmc">5917749</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180&#x2013;190 (2019). Together with Klim et al. (2019), this study was among the first to establish a functional connection between the loss of TDP-43 splicing function and the occurrence of cryptic splicing events in stathmin-2 that promoted disease pathology in both sporadic and familial ALS.</Citation><ArticleIdList><ArticleId IdType="pubmed">30643298</ArticleId><ArticleId IdType="pmc">6348009</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim, J. R. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 22, 167&#x2013;179 (2019). Together with Melamed et al. (2019), this study was among the first to establish a functional connection between the loss of TDP-43 splicing function and the occurrence of cryptic splicing events in stathmin-2 that promoted disease pathology in both sporadic and familial ALS.</Citation><ArticleIdList><ArticleId IdType="pubmed">30643292</ArticleId><ArticleId IdType="pmc">7153761</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, A.-L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137 (2022). Together with Ma et al. (2022), this study links TDP-43 depletion with dysregulated splicing of UNC13a, a key neuronal protein that is functionally impaired in patients with FTD with TDP-43 proteinopathy.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197628</ArticleId><ArticleId IdType="pmc">8891020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, X. R. et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature 603, 124&#x2013;130 (2022). Together with Brown et al. (2022), this study links TDP-43 depletion with dysregulated splicing of UNC13a, a key neuronal protein that is functionally impaired in patients with FTD with TDP-43 proteinopathy.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197626</ArticleId><ArticleId IdType="pmc">8891019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki, S. &amp; Sobue, G. Importance of functional loss of FUS in FTLD/ALS. Front. Mol. Biosci. 5, 44 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29774215</ArticleId><ArticleId IdType="pmc">5943504</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey, J. et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 48, 6889&#x2013;6905 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32479602</ArticleId><ArticleId IdType="pmc">7337901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R. &amp; Gitler, A. D. ALS genetics: gains, losses, and implications for future therapies. Neuron 108, 822&#x2013;842 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32931756</ArticleId><ArticleId IdType="pmc">7736125</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. &amp; Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104&#x2013;116 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35075293</ArticleId><ArticleId IdType="pmc">8799464</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson, H. in Handbook of Clinical Neurology, Vol. 147 (eds Geschwind, D. H., Paulson, H. L. &amp; Klein, C.) Ch. 9, 105&#x2013;123 (Elsevier, 2018).</Citation></Reference><Reference><Citation>Zhang, N. &amp; Ashizawa, T. RNA toxicity and foci formation in microsatellite expansion diseases. Curr. Opin. Genet. Dev. 44, 17&#x2013;29 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28208060</ArticleId><ArticleId IdType="pmc">5447490</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187&#x2013;193 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20098426</ArticleId><ArticleId IdType="pmc">2852634</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, C. &amp; Hilton-Jones, D. Myotonic dystrophy: diagnosis, management and new therapies. Curr. Opin. Neurol. 27, 599 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25121518</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin, M. et al. MBNL sequestration by toxic RNAs and RNA mis-processing in the myotonic dystrophy brain. Cell Rep. 12, 1159&#x2013;1168 (2015). This study shows that MBNL2 proteins are directly sequestered by microsatellite expansion RNAs in the myotonic dystrophy brain, resulting in disruption of the normal MBNL2 function in regulating alternative splicing.</Citation><ArticleIdList><ArticleId IdType="pubmed">26257173</ArticleId><ArticleId IdType="pmc">4545389</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlet-B, N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45&#x2013;53 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12150906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanadia, R. N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978&#x2013;1980 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14671308</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg, J., Jiang, H., Thornton, C. A. &amp; Cannon, S. C. Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology 63, 2371&#x2013;2375 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15623702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashizawa, T., &#xd6;z, G. &amp; Paulson, H. L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat. Rev. Neurol. 14, 590&#x2013;605 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30131520</ArticleId><ArticleId IdType="pmc">6469934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale, M. A., Johnson, N. E. &amp; Berglund, J. A. Repeat-associated RNA structure and aberrant splicing. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 194405 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31323433</ArticleId><ArticleId IdType="pmc">7099610</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, D., McIntosh, C. S., Mastaglia, F. L., Wilton, S. D. &amp; Aung-Htut, M. T. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. Transl. Neurodegener. 10, 16 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34016162</ArticleId><ArticleId IdType="pmc">8136212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi, S. J., Flower, M. D., Ross, C. A. &amp; Wild, E. J. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev. Neurol. 16, 529&#x2013;546 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32796930</ArticleId></ArticleIdList></Reference><Reference><Citation>Elorza, A. et al. Huntington&#x2019;s disease-specific mis-splicing unveils key effector genes and altered splicing factors. Brain 144, 2009&#x2013;2023 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33725094</ArticleId><ArticleId IdType="pmc">8370404</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling, J. et al. Deregulated splicing is a major mechanism of RNA-induced toxicity in Huntington&#x2019;s disease. J. Mol. Biol. 431, 1869&#x2013;1877 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30711541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA 110, 2366&#x2013;2370 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23341618</ArticleId><ArticleId IdType="pmc">3568346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franich, N. R. et al. Phenotype onset in Huntington&#x2019;s disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. J. Neurosci. Res. 97, 1590&#x2013;1605 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31282030</ArticleId><ArticleId IdType="pmc">6801054</ArticleId></ArticleIdList></Reference><Reference><Citation>Neueder, A. et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington&#x2019;s disease patients. Sci. Rep. 7, 1307 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28465506</ArticleId><ArticleId IdType="pmc">5431000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason, M. A. et al. Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington&#x2019;s disease models. Sci. Rep. 10, 14057 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32820193</ArticleId><ArticleId IdType="pmc">7441155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, X. et al. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice. Neuron 110, 1173&#x2013;1192.e7 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35114102</ArticleId><ArticleId IdType="pmc">9462388</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin, A. A. Treating disease at the RNA level with oligonucleotides. N. Engl. J. Med. 380, 57&#x2013;70 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30601736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamecnik, P. C. &amp; Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280&#x2013;284 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">75545</ArticleId><ArticleId IdType="pmc">411230</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson, M. L. &amp; Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75, 285&#x2013;288 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">75546</ArticleId><ArticleId IdType="pmc">411231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257&#x2013;271 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26573217</ArticleId><ArticleId IdType="pmc">5064753</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma, A. Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases. Ann. Indian Acad. Neurol. 21, 3&#x2013;8 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29720791</ArticleId><ArticleId IdType="pmc">5909143</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfano, L. N. et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine 98, e15858 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31261494</ArticleId><ArticleId IdType="pmc">6617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Morena, C. et al. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann. Clin. Transl. Neurol. 7, 1738&#x2013;1752 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33325654</ArticleId><ArticleId IdType="pmc">7480922</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel, R. S. et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723&#x2013;1732 (2017). This study reported the clinical efficacy and safety of a splice-switching ASO for spinal muscular atrophy in infants, supporting the modulation of targeted pre-mRNA splicing as a therapeutic approach for treating genetic disorders.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644&#x2013;1652 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31597037</ArticleId><ArticleId IdType="pmc">6961983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634&#x2013;1644 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20624852</ArticleId><ArticleId IdType="pmc">2912561</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodkey, K., Aslesh, T., Maruyama, R. &amp; Yokota, T. in Exon Skipping and Inclusion Therapies: Methods and Protocols (eds Yokota, T. &amp; Maruyama, R.) 69&#x2013;76 (Springer, 2018).</Citation></Reference><Reference><Citation>Ottesen, E. W. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl. Neurosci. 8, 1&#x2013;6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28400976</ArticleId><ArticleId IdType="pmc">5382937</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xf1;&#xe9;-Pou, M. et al. Targeting splicing in the treatment of human disease. Genes 8, 87 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28245575</ArticleId><ArticleId IdType="pmc">5368691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch, K. M. et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90, 941&#x2013;947 (2016). This study shows that increasing 4R-tau expression, without altering the total tau level, leads to tau pathology and abnormal behaviour in a mouse model, providing direct evidence supporting the role of splicing deregulation in tauopathy.</Citation><ArticleIdList><ArticleId IdType="pubmed">27210553</ArticleId><ArticleId IdType="pmc">5040069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. L. et al. Targeting amyloid-&#x3b2; precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-&#x3b2; production. Mol. Ther. 26, 1539&#x2013;1551 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29628304</ArticleId><ArticleId IdType="pmc">5986716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring, S. et al. The secreted &#x3b2;-amyloid precursor protein ectodomain APPs&#x3b1; is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817&#x2013;7826 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17634375</ArticleId><ArticleId IdType="pmc">6672885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan, N. B. &amp; Siegel, G. J. Antisense inhibition at the &#x3b2;-secretase-site of &#x3b2;-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 146, 143&#x2013;151 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17303345</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoutsali, E. et al. Antisense oligonucleotide-induced amyloid precursor protein splicing modulation as a therapeutic approach for Dutch-type cerebral amyloid angiopathy. Nucleic Acid Ther. 31, 351&#x2013;363 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34061681</ArticleId><ArticleId IdType="pmc">8823675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, H. et al. &#x3b2;-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81, 525&#x2013;531 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson, G. R. et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the &#x3b2;-amyloid precursor protein. Neuroscience 90, 1&#x2013;13 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller, U. et al. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell 79, 755&#x2013;765 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Magara, F. et al. Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the &#x3b2;-amyloid-precursor protein. Proc. Natl Acad. Sci. USA 96, 4656&#x2013;4661 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10200318</ArticleId><ArticleId IdType="pmc">16388</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. et al. Truncating mutations in APP cause a distinct neurological phenotype. Ann. Neurol. 80, 456&#x2013;460 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27422356</ArticleId><ArticleId IdType="pmc">7034636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell, K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Discov. 20, 412&#x2013;413 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34012000</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller, C. G. et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat. Commun. 13, 1150 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35241644</ArticleId><ArticleId IdType="pmc">8894458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId><ArticleId IdType="pmc">7116650</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, E. S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA 110, E736&#x2013;E745 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23382207</ArticleId><ArticleId IdType="pmc">3581922</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio, M. et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26192745</ArticleId><ArticleId IdType="pmc">4830686</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo, O. et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 7, e829 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32669313</ArticleId><ArticleId IdType="pmc">7371375</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia, A. M. et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 7, 10046 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28855684</ArticleId><ArticleId IdType="pmc">5577269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan, R. et al. Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions. Acta Neuropathol. 143, 383&#x2013;401 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34961893</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese, A. et al. Whole transcriptome profiling of late-onset Alzheimer&#x2019;s disease patients provides insights into the molecular changes involved in the disease. Sci. Rep. 8, 4282 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29523845</ArticleId><ArticleId IdType="pmc">5844946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan, Y.-W. et al. Meta-analysis of the Alzheimer&#x2019;s disease human brain transcriptome and functional dissection in mouse models. Cell Rep. 32, 107908 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32668255</ArticleId><ArticleId IdType="pmc">7428328</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj, T. et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat. Genet. 50, 1584&#x2013;1592 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30297968</ArticleId><ArticleId IdType="pmc">6354244</ArticleId></ArticleIdList></Reference><Reference><Citation>Salemi, M. et al. A transcriptome analysis of mRNAs and long non-coding RNAs in patients with Parkinson&#x2019;s disease. Int. J. Mol. Sci. 23, 1535 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35163455</ArticleId><ArticleId IdType="pmc">8836138</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaab, E. &amp; Schneider, R. Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson&#x2019;s disease. Neurobiol. Dis. 74, 1&#x2013;13 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25447234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, E. et al. Transcriptomic profiling of differentially expressed genes and related pathways in different brain regions in Parkinson&#x2019;s disease. Neurosci. Lett. 732, 135074 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32446776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, L. et al. Transcriptome sequencing reveals aberrant alternative splicing in Huntington&#x2019;s disease. Hum. Mol. Genet. 25, 3454&#x2013;3466 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27378699</ArticleId><ArticleId IdType="pmc">5179942</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, L., Fang, L., Liu, Q., Torshizi, A. D. &amp; Wang, K. Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington&#x2019;s disease. Genes Dis. 9, 479&#x2013;493 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35224162</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder, P. et al. Integrated genomics and proteomics to define huntingtin CAG length-dependent networks in HD mice. Nat. Neurosci. 19, 623&#x2013;633 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26900923</ArticleId><ArticleId IdType="pmc">5984042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram, M. et al. Cerebellar transcriptome profiles of ATXN1 transgenic mice reveal SCA1 disease progression and protection pathways. Neuron 89, 1194&#x2013;1207 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26948890</ArticleId><ArticleId IdType="pmc">4795980</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich, J. et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight 3, e123193 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30385727</ArticleId><ArticleId IdType="pmc">6238731</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger, A. et al. mRNA trans-splicing in gene therapy for genetic diseases. Wiley Interdiscip. Rev. RNA 7, 487&#x2013;498 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27018401</ArticleId><ArticleId IdType="pmc">5071737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemaladewi, D. U. et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat. Med. 23, 984&#x2013;989 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28714989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Martin, T. et al. Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc. Natl Acad. Sci. USA 102, 15659&#x2013;15664 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16230627</ArticleId><ArticleId IdType="pmc">1266082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Martin, T. et al. Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans- splicing. Hum. Mol. Genet. 18, 3266&#x2013;3273 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19498037</ArticleId><ArticleId IdType="pmc">2722988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wally, V., Murauer, E. M. &amp; Bauer, J. W. Spliceosome-mediated trans-splicing: the therapeutic cut and paste. J. Investig. Dermatol. 132, 1959&#x2013;1966 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22495179</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, J. et al. Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol. Cell 72, 380&#x2013;394.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30293782</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastidar, S. et al. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res. 46, 8275&#x2013;8298 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29947794</ArticleId><ArticleId IdType="pmc">6144820</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes, M., Sanford, B. L., Comiskey, D. F. &amp; Chandler, D. S. RNA splicing and disease: animal models to therapies. Trends Genet. 35, 68&#x2013;87 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30466729</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra, R. et al. Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9. Cell 170, 899&#x2013;912.e10 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28803727</ArticleId><ArticleId IdType="pmc">5873302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>